Alpha Cognition (ACOG) investor relations material

Corporate overview and strategy

• Focuses on developing treatments for neurodegenerative diseases, especially Alzheimer's, with limited current options.

• Commercial launch of ZUNVEYL®, the first oral Alzheimer's treatment approved in 15 years.

• Targets a $2B total addressable market, emphasizing the long-term care (LTC) segment, which represents 36% of the market.

• Multiple country approvals for ZUNVEYL expected in 2026, with a strong clinical pipeline supporting expansion.

• Sufficient cash reserves to fund operations through expected operating breakeven in 2027.

Product profile and differentiation

• ZUNVEYL is a novel galantamine prodrug designed to minimize side effects and improve long-term outcomes.

• Dual mechanism of action: acetylcholinesterase inhibition and modulation of nicotinic receptor sensitivity, enhancing cognitive and behavioral symptoms.

• Delayed release formulation avoids gastrointestinal and insomnia side effects common in existing therapies.

• Demonstrates significant and sustained improvement in cognitive and functional performance, with no impact on sleep.

• Positioned as a compelling alternative to legacy treatments, addressing high unmet needs among patients and physicians.

Commercial performance and market access

• Over 9,500 ZUNVEYL prescriptions filled in the first three quarters post-launch, with a 64% quarterly increase in Q4 2025.

• Q4 2025 revenue reached $2.9M, with total 2025 revenues at $10.2M.

• Early payor contracts secured, with 45% potential Medicare coverage and over 25M potential Medicare lives.

• 70% of LTC lives have access to ZUNVEYL with zero co-pay, and 90% of prescriptions currently approved.

• Commercialization strategy leverages a focused sales force targeting 5,000 nursing homes and 3,000 healthcare providers.